Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 2Resectable Esophageal Cancer 1Prostatic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1

Interventions

Temozolomide 8sargramostim 2pembrolizumab 2Radiotherapy 2Radiation 2veliparib 1selinexor 1montanide ISA 51 1lonafarnib 1Vorinostat 1Sucrose 1Sonication 1Sodium Chloride 1Serotonin Antagonists 1Salts 1Photons 1Perfusion Magnetic Resonance Imaging 1Olanzapine 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1Loperamide 1Lomustine 1Irinotecan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Drug Therapy 1Cyclophosphamide 1Colony-Stimulating Factors 1Carboplatin 1CLR1404 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gliosarcoma × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Epitopoietic Research Corporation

Phase 2 Active not recruiting
84 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡